AU2017359018C1 - Treatment of CNS diseases with SGC stimulators - Google Patents

Treatment of CNS diseases with SGC stimulators Download PDF

Info

Publication number
AU2017359018C1
AU2017359018C1 AU2017359018A AU2017359018A AU2017359018C1 AU 2017359018 C1 AU2017359018 C1 AU 2017359018C1 AU 2017359018 A AU2017359018 A AU 2017359018A AU 2017359018 A AU2017359018 A AU 2017359018A AU 2017359018 C1 AU2017359018 C1 AU 2017359018C1
Authority
AU
Australia
Prior art keywords
disease
disorder
compound
cns
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017359018A
Other languages
English (en)
Other versions
AU2017359018A1 (en
AU2017359018B2 (en
Inventor
Peter Germano
Rajesh R. Iyengar
Joon Jung
Thomas Wai-Ho Lee
Nicholas Robert Perl
Maria D. Ribadeneira
Kim TANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tisento Therapeutics Inc
Original Assignee
Tisento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tisento Therapeutics Inc filed Critical Tisento Therapeutics Inc
Publication of AU2017359018A1 publication Critical patent/AU2017359018A1/en
Publication of AU2017359018B2 publication Critical patent/AU2017359018B2/en
Assigned to TISENTO THERAPEUTICS INC. reassignment TISENTO THERAPEUTICS INC. Request for Assignment Assignors: CYCLERION THERAPEUTICS, INC.
Priority to AU2023270267A priority Critical patent/AU2023270267A1/en
Application granted granted Critical
Publication of AU2017359018C1 publication Critical patent/AU2017359018C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017359018A 2016-11-08 2017-11-07 Treatment of CNS diseases with SGC stimulators Active AU2017359018C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023270267A AU2023270267A1 (en) 2016-11-08 2023-11-22 Treatment of CNS diseases with sGC stimulators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08
US62/419,059 2016-11-08
PCT/US2017/060299 WO2018089328A1 (en) 2016-11-08 2017-11-07 Treatment of cns diseases with sgc stimulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023270267A Division AU2023270267A1 (en) 2016-11-08 2023-11-22 Treatment of CNS diseases with sGC stimulators

Publications (3)

Publication Number Publication Date
AU2017359018A1 AU2017359018A1 (en) 2019-05-30
AU2017359018B2 AU2017359018B2 (en) 2023-08-31
AU2017359018C1 true AU2017359018C1 (en) 2023-12-21

Family

ID=60452769

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017359018A Active AU2017359018C1 (en) 2016-11-08 2017-11-07 Treatment of CNS diseases with SGC stimulators
AU2023270267A Abandoned AU2023270267A1 (en) 2016-11-08 2023-11-22 Treatment of CNS diseases with sGC stimulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023270267A Abandoned AU2023270267A1 (en) 2016-11-08 2023-11-22 Treatment of CNS diseases with sGC stimulators

Country Status (19)

Country Link
US (3) US11690828B2 (enExample)
EP (1) EP3538096B1 (enExample)
JP (2) JP7150740B2 (enExample)
KR (1) KR102475124B1 (enExample)
CN (1) CN110267658B (enExample)
AU (2) AU2017359018C1 (enExample)
BR (1) BR112019009449A2 (enExample)
CA (1) CA3042548A1 (enExample)
CL (1) CL2019001256A1 (enExample)
EA (1) EA201991147A1 (enExample)
ES (1) ES2972711T3 (enExample)
IL (1) IL266275B2 (enExample)
MA (1) MA46752A (enExample)
MX (2) MX2019005342A (enExample)
NZ (1) NZ753434A (enExample)
PH (1) PH12019501016A1 (enExample)
SG (1) SG10202104865UA (enExample)
TW (1) TWI812601B (enExample)
WO (1) WO2018089328A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538520B1 (en) * 2016-11-08 2025-12-31 Tisento Therapeutics Inc. CGS STIMULATORS
US11389449B2 (en) 2017-09-14 2022-07-19 Cyclerion Therapeutics, Inc. Treatment of metabolic syndrome with an sGC stimulator
CA3103676A1 (en) 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of mitochonrial disorders
US20220087970A1 (en) * 2019-01-18 2022-03-24 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
WO2021111419A1 (en) * 2019-12-05 2021-06-10 Cadila Healthcare Limited Modified release pharmaceutical compositions of riociguat
JP7412583B2 (ja) 2020-02-07 2024-01-12 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
US20250064799A1 (en) * 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
EP4658253A1 (en) * 2023-02-03 2025-12-10 R.P. Scherer Technologies, LLC Osmotic pharmaceutical capsules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124854A1 (de) * 2006-04-27 2007-11-08 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte pyrazol-derivate und ihre verwendung
WO2017106175A2 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
DE3660408D1 (en) 1985-02-27 1988-08-25 Oerlikon Buehrle Ag Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
KR100634069B1 (ko) 1998-12-17 2006-10-16 알자 코포레이션 다중 코팅에 의한, 액체 충진 젤라틴 캡슐로부터 제어방출 시스템으로의 전환
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2534371A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
CA2711134A1 (en) 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
ES2885003T3 (es) * 2016-09-02 2021-12-13 Cyclerion Therapeutics Inc Estimuladores de SGC fusionados bicíclicos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124854A1 (de) * 2006-04-27 2007-11-08 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte pyrazol-derivate und ihre verwendung
WO2017106175A2 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. R. Roberts, et al.: "Acidic triazoles as soluble guanylate cyclase stimulators", Bioorganic & Medicinal Chemistry Letters. 2011, 21(13): 6515-6518. DOI: 10.1016/J.BMCL.2011.08.071. *

Also Published As

Publication number Publication date
MX2022010852A (es) 2022-09-27
WO2018089328A8 (en) 2019-03-28
TWI812601B (zh) 2023-08-21
AU2023270267A1 (en) 2023-12-07
NZ753434A (en) 2025-10-31
JP7150740B2 (ja) 2022-10-11
TW201822765A (zh) 2018-07-01
CN110267658B (zh) 2024-02-02
WO2018089328A1 (en) 2018-05-17
AU2017359018A1 (en) 2019-05-30
MA46752A (fr) 2019-09-18
EP3538096B1 (en) 2024-02-28
JP2022160605A (ja) 2022-10-19
US20250108040A1 (en) 2025-04-03
EP3538096C0 (en) 2024-02-28
CL2019001256A1 (es) 2019-10-04
KR102475124B1 (ko) 2022-12-08
CA3042548A1 (en) 2018-05-17
US20230381153A1 (en) 2023-11-30
IL266275A (en) 2019-06-30
ES2972711T3 (es) 2024-06-14
JP2019534327A (ja) 2019-11-28
AU2017359018B2 (en) 2023-08-31
MX2019005342A (es) 2019-10-02
KR20190094167A (ko) 2019-08-12
SG10202104865UA (en) 2021-06-29
EA201991147A1 (ru) 2019-11-29
EP3538096A1 (en) 2019-09-18
US20190343813A1 (en) 2019-11-14
CN110267658A (zh) 2019-09-20
IL266275B2 (en) 2023-12-01
BR112019009449A2 (pt) 2019-07-30
US11690828B2 (en) 2023-07-04
PH12019501016A1 (en) 2019-09-09
IL266275B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
US11731977B2 (en) SGC stimulators
US20250108040A1 (en) TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
US20260000653A1 (en) TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
HK40013531B (en) Treatment of cns diseases with sgc stimulators
HK40013531A (en) Treatment of cns diseases with sgc stimulators
HK40061428B (en) Fused bicyclic sgc stimulators
EA041012B1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
BR112019004468B1 (pt) Estimulantes de sgc
HK40010650A (en) Fused bicyclic sgc stimulators

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 SEP 2023

PC1 Assignment before grant (sect. 113)

Owner name: TISENTO THERAPEUTICS INC.

Free format text: FORMER APPLICANT(S): CYCLERION THERAPEUTICS, INC.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 SEP 2023

FGA Letters patent sealed or granted (standard patent)